The Resistant Depression Response to Esketamine Assessing Metabolomics (ReDREAM) Project— Untargeted Metabolomics to Identify Biomarkers of Treatment Response to Intranasal Esketamine in Individuals with Treatment-Resistant Depression: A Study Protocol

<body> </body>